Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)

Expert Reviews in Molecular Medicine

Volumn 12, Issue , 2010, Pages

  Pollard, Courtney ^a   Smith, Steven C ^a   Theodorescu, Dan ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; PROTEIN PATCHED 1; ROMIDEPSIN; SELUMETINIB; SORAFENIB; HRAS PROTEIN, HUMAN; PROTEIN P21;

ANTINEOPLASTIC ACTIVITY; BLADDER TUMOR; CANCER INHIBITION; CANCER INVASION; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; CDKN2A GENE; CDKN2B GENE; CHROMOSOME 9; CHROMOSOME 9P; CHROMOSOME 9Q; COLON CANCER; COLORECTAL CANCER; COLORECTAL TUMOR; DBC1 GENE; FIBROBLAST GROWTH FACTOR RECEPTOR 3 GENE; GAIN OF FUNCTION MUTATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; INTRACELLULAR SIGNALING; LUNG TUMOR; MELANOMA; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; MUTATOR GENE; NON MUSCLE INVASIVE UROTHELIAL CARCINOMA; NONHUMAN; ONCOGENE H RAS; OVARY CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; PTCH1 GENE; REVIEW; THYROID CANCER; TP53 GENE; TRANSITIONAL CELL CARCINOMA; TSC1 GENE; TUMOR SUPPRESSOR GENE; GENETICS; METABOLISM; MUSCLE; PATHOLOGY; UROTHELIUM;

CARCINOMA, TRANSITIONAL CELL; CHROMOSOMES, HUMAN, PAIR 9; HUMANS; MUSCLES; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; UROTHELIUM;

EID: 77953169090     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399410001407     Document Type: Review

References (150)

1. Parkin, D.M. et al. (2005) Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 55, 74-108 (Pubitemid 40372904)
2. Montironi, R. and Lopez-Beltran, A. (2005) The 2004 WHO classification of bladder tumors: a summary and commentary. International Journal of Surgical Pathology 13, 143-153 (Pubitemid 40617541)
3. Jemal, A. et al. (2009) Cancer statistics, 2009. CA:A Cancer Journal for Clinicians 59, 225-249
4. Sonny, L.J. and Samuel, M.C. (1997) Epidemiology and etiology of bladder cancer. Seminars in Surgical Oncology 13, 291-298
5. Kamat, A.M. and Lamm, D.L. (2000) Intravesical therapy for bladder cancer. Urology 55, 161-168 (Pubitemid 30069908)
6. Pasin, E. et al. (2008) Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Reviews in Urology 10, 31-43
7. Sengelov, L., Kamby, C. and von der Maase, H. (1996) Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma. Journal of Urology 155, 111-114 (Pubitemid 126426442)
8. Steinberg, G.D., Trump, D.L. and Cummings, K.B. (1992) Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. Urologic Clinics of North America 19, 735-746
9. Liebert, M. and Seigne, J. (1996) Characteristics of invasive bladder cancers: histological and molecular markers. Seminars in Urologic Oncology 14, 62-72 (Pubitemid 26154973)
10. Koss, L.G. (1992) Bladder cancer from a perspective of 40 years. Journal of Cellular Biochemistry (Suppl) 16I, 23-29
11. Wu, X-R. (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nature Reviews Cancer 5, 713-725
12. Bakkar, A.A. et al. (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Research 63, 8108-8112 (Pubitemid 37549454)
13. Lamy, A. et al. (2006) Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. Journal of Urology 176, 2686-2689 (Pubitemid 44755065)
14. Hernandez, S. et al. (2005) FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clinical Cancer Research 11, 5444-5450 (Pubitemid 41060820)
15. Karsten, Z. et al. (2009) Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. International Journal of Cancer 125, 2095-2103
16. Tsai, Y.C. et al. (1990) Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Research 50, 44-47 (Pubitemid 20029991)
17. Cairns, P., Shaw, M.E. and Knowles, M.A. (1993) Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 8, 1083-1085
18. Miyao, N. et al. (1993) Role of chromosome 9 in human bladder cancer. Cancer Research 53, 4066-4070 (Pubitemid 23267712)
19. Llnnenbach, A.J. et al. (1993) Characterization of chromosome 9 deletions in transitional cell carcinoma by microsatellite assay. Human Molecular Genetics 2, 1407-1411
20. Orlow, I. et al. (1994) Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Research 54, 2848-2851 (Pubitemid 24187760)
21. Habuchi, T. et al. (1995) Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene 11, 1671-1674
22. Keen, A.J. and Knowles, M.A. (1994) Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9, 2083-2088 (Pubitemid 24194178)
23. Simoneau, A.R. et al. (1996) Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Research 56, 5039-5043 (Pubitemid 26374446)
24. Serrano, M., Hannon, G.J. and Beach, D. (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704-707 (Pubitemid 24036021)
25. Hannon, G.J. and Beach, D. (1994) p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371, 257-261
26. Schulze, A. et al. (1994) Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1. Oncogene 9, 3475-3482
27. Johnson, D.G. (1995) Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity. Oncogene 11, 1685-1692
28. Gonzalez-Zulueta, M. et al. (1995) high frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. Journal of the National Cancer Institute 87, 1383-1393
29. Gonzalez-Zulueta, M. et al. (1995) Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Research 55, 4531-4535
30. Orlow, I. et al. (1995) Deletion of the p16 and p15 genes in human bladder tumors. Journal of the National Cancer Institute 87, 1524-1529
31. Southgate, J. et al. (1995) Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines. British Journal of Cancer 72, 1214-1218
32. Le Frere-Belda, M.A. et al. (2001) p15INK4b in bladder carcinomas: decreased expression in superficial tumours. British Journal of Cancer 85, 1515-1521 (Pubitemid 34001583)
33. Hornigold, N. et al. (1999) Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 18, 2567-2561
34. Hornigold, N. et al. (1997) A 1.7-megabase sequence-ready cosmid contig covering the TSC1 candidate region in 9q34. Genomics 41, 385-389
35. van Slegtenhorst, M. et al. (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277, 805-808
36. Knowles, M.A. et al. (2003) Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Research 63, 7652-7656 (Pubitemid 37466691)
37. Pymar, L.S. et al. (2008) Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms. Human Molecular Genetics 17, 2006-2017 (Pubitemid 351865849)
38. Adachi, H. et al. (2003) Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. Journal of Urology 170, 601-604 (Pubitemid 36870268)
39. Habuchi, T., Yoshida, O. and Knowles, M.A. (1997) A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: localization of the candidate region within a single 840 kb YAC. Human Molecular Genetics 6, 913-919 (Pubitemid 27239077)
40. Habuchi, T. et al. (1998) Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics 48, 277-288 (Pubitemid 28180727)
41. Simoneau, M. et al. (1999) Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene 18, 157-163 (Pubitemid 29060589)
42. Joanne, E. et al. (2002) Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. Journal of Pathology 196, 380-385
43. Friedrich, M.G. et al. (2001) Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. European Urology 40, 518-524 (Pubitemid 34289750)
44. Bartoletti, R. et al. (2007) Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. Journal of Surgical Research 143, 422-427 (Pubitemid 350110444)
45. Bartlett, J.M. et al. (1998) Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? British Journal of Cancer 77, 2193-2198 (Pubitemid 28263940)
46. Lopez-Beltran, A. et al. (2008) Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium. Journal of Pathology 215, 263-272 (Pubitemid 351956707)
47. Eswarakumar, V.P., Lax, I. and Schlessinger, J. (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine & Growth Factor Reviews 16, 139-149 (Pubitemid 40616112)
48. Karuppiah, K. and David, G. (2000) FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models. IUBMB Life 49, 197-205
49. L'Hôte, C.G.M. and Knowles, M.A. (2005) Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Experimental Cell Research 304, 417-431 (Pubitemid 40321120)
50. Murgue, B. et al. (1994) Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium. Cancer Research 54, 5206-5211 (Pubitemid 24313501)
51. Rousseau, F. et al. (1994) Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371, 252-254 (Pubitemid 24293024)
52. Shiang, R. et al. (1994) Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78, 335-342 (Pubitemid 24241100)
53. Bellus, G.A. et al. (1995) A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nature Genetics 10, 357-359
54. Superti-Furga, A. et al. (1995) A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. European Journal of Pediatrics 154, 215-219
55. Ikegawa, S. et al. (1995) Mutations of the fibroblast growth factor receptor-3 gene in one familial and six sporadic cases of achondroplasia in Japanese patients. Human Genetics 96, 309-311
56. Tavormina, P.L. et al. (1995) Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nature Genetics 9, 321-328
57. Tavormina, P.L. et al. (1995) Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. Human Molecular Genetics 4, 2175-2177
58. Fuu-Jen, T. et al. (1999) Mutations in the fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia, hypochondroplasia, and thanatophoric dysplasia: Taiwanese data. American Journal of Medical Genetics 86, 300-301
59. Bonaventure, J. et al. (1996) Common mutations in the fibroblast growth factor receptor 3 (FGFR 3) gene account for achondroplasia, hypochondroplasia, and thanatophoric dwarfism. American Journal of Medical Genetics 63, 148-154
60. Cappellen, D. et al. (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genetics 23, 18-20
61. Karoui, M. et al. (2001) No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene 20, 5059-5061 (Pubitemid 32769796)
62. Sibley, K., Stern, P. and Knowles, M.A. (2001) Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene 20, 4416-4418 (Pubitemid 32726885)
63. Webster, M.K. and Donoghue, D.J. (1997) FGFR activation in skeletal disorders: too much of a good thing. Trends in Genetics 13, 178-182 (Pubitemid 27219582)
64. Naski, M.C. et al. (1996) Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nature Genetics 13, 233-237 (Pubitemid 26166160)
65. Agazie, Y.M. et al. (2003) The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene 22, 6909-6918 (Pubitemid 37386691)
66. Kanai, M. et al. (1997) Signal transduction pathway of human fibroblast growth factor receptor 3. Journal of Biological Chemistry 272, 6621-6628
67. Jebar, A.H. et al. (2005) FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24, 5218-5225 (Pubitemid 41192438)
68. van Rhijn, B.W.G. et al. (2001) The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Research 61, 1265-1268
69. Billerey, C. et al. (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. American Journal of Pathology 158, 1955-1959 (Pubitemid 32545179)
70. Spruck, C.H., III, et al. (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Research 54, 784-788
71. Reznikoff, C.A. et al. (1996) A molecular genetic model of human bladder cancer pathogenesis. Seminars in Oncology 23, 571-584 (Pubitemid 26362217)
72. Lee, R. and Droller, M.J. (2000) The natural history of bladder cancer. Implications for therapy. Urologic Clinics of North America 27, 1-13 (Pubitemid 30085993)
73. Sanchez-Carbayo, M. et al. (2002) Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Research 62, 6973-6980 (Pubitemid 35424089)
74. Sanchez-Carbayo, M. et al. (2003) Gene discovery in bladder cancer progression using cDNA microarrays. American Journal of Pathology 163, 505-516 (Pubitemid 36909413)
75. Dyrskjøt, L. et al. (2003) Identifying distinct classes of bladder carcinoma using microarrays. Nature Genetics 33, 90-96 (Pubitemid 36068689)
76. Takahiro, K. et al. (2001) The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 92, 2555-2561
77. van Rhijn, B.W. et al. (2002) Frequent FGFR3 mutations in urothelial papilloma. Journal of Pathology 198, 245-251
78. Cordon-Cardo, C. et al. (1994) p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. International Journal of Cancer 56, 347-353
79. Spiess, P.E. and Czerniak, B. (2006) Dual-track pathway of bladder carcinogenesis: practical implications. Archives of Pathology and Laboratory Medicine 130, 844-852 (Pubitemid 43887006)
80. van Rhijn, B.W.G. et al. (2004) FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Research 64, 1911-1914
81. Mhawech-Fauceglia, P. et al. (2006) FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. European Journal of Surgical Oncology 32, 231-237 (Pubitemid 43257130)
82. Lott, S. et al. (2009) FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. Modern Pathology 22, 627-632
83. van Rhijn, B.W.G. et al. (2003) Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. Journal of Clinical Oncology 21, 1912-1921
84. Hernandez, S. et al. (2006) Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. Journal of Clinical Oncology 24, 3664-3671 (Pubitemid 46630542)
85. Burger, M. et al. (2008) Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. European Urology 54, 835-844
86. Francesca, B. et al. (2008) Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer 112, 636-644
87. Gazdar, A.F. et al. (2004) Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends in Molecular Medicine 10, 481-486 (Pubitemid 39303620)
88. Weinstein, I.B., Joe, A. and Felsher, D. (2008) Oncogene addiction. Cancer Research 68, 3077-3080
89. Trudel, S. et al. (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105, 2941-2948 (Pubitemid 40446289)
90. Mohammadi, M. et al. (1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276, 955-960 (Pubitemid 27209095)
91. Grand, E.K. et al. (2004) Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 18, 962-966 (Pubitemid 38714621)
92. Trudel, S. et al. (2004) Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103, 3521-3528 (Pubitemid 38525687)
93. Mohammadi, M. et al. (1998) Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO Journal 17, 5896-5904 (Pubitemid 28474784)
94. Laird, A.D. et al. (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Research 60, 4152-4160 (Pubitemid 30636598)
95. Rauchenberger, R. et al. (2003) Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. Journal of Biological Chemistry 278, 38194-38205 (Pubitemid 37221708)
96. Martínez -Torrecuadrada, J. et al. (2005) Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clinical Cancer Research 11, 6280-6290
97. Gorbenko, O. et al. (2009) Generation of monoclonal antibody targeting fibroblast growth factor receptor 3. Hybridoma 28, 295-300
98. Qing, J. et al. (2009) Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. Journal of Clinical Investigation 119, 1216-1229
99. Martínez-Torrecuadrada, J.L. et al. (2008) Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Molecular Cancer Therapeutics 7, 862-873 (Pubitemid 351551039)
100. Herrera, R. and Sebolt-Leopold, J.S. (2002) Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends in Molecular Medicine 8, S27-S31 (Pubitemid 34297075)
101. Jiang, B. et al. (2009) Chapter 2 PI3K/PTEN signaling in angiogenesis and tumorigenesis. Advances in Cancer Research 102, 19-65
102. Rusanescu, G. et al. (2001) Regulation of Ras signaling specificity by protein kinase C. Molecular and Cellular Biology 21, 2650-2658 (Pubitemid 32244910)
103. Feinberg, A.P. et al. (1983) Mutation affecting the 12th amino acid of the c-Ha-ras oncogene product occurs infrequently in human cancer. Science 220, 1175-1177 (Pubitemid 13097205)
104. Fujita, J. et al. (1984) Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours. Nature 309, 464-466 (Pubitemid 14102454)
105. Fujita, J. et al. (1985) Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors. Proceedings of the National Academy of Sciences of the United States of America 82, 3849-3853 (Pubitemid 15246449)
106. Visvanathan, K.V., Pocock, R.D. and Summerhayes, I.C. (1988) Preferential and novel activation of H-ras in human bladder carcinomas. Oncogene Research 3, 77-86 (Pubitemid 19036481)
107. Joyce, A.D. et al. (1989) Detection of altered H-ras proteins in human tumors using western blot analysis. Laboratory Investigation 61, 212-218 (Pubitemid 19222752)
108. Saito, S. et al. (1997) Screening of H-ras gene point mutations in 50 cases of bladder carcinoma. International Journal of Urology 4, 178-185 (Pubitemid 27182660)
109. Boulalas, I. et al. (2009) Activation of RAS family genes in urothelial carcinoma. Journal of Urology 181, 2312-2319
110. Tabin, C.J. et al. (1982) Mechanism of activation of a human oncogene. Nature 300, 143-149 (Pubitemid 12006346)
111. Reddy, E.P. et al. (1982) A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300, 149-152 (Pubitemid 12006347)
112. Taparowsky, E. et al. (1982) Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature 300, 762-765 (Pubitemid 13224357)
113. Theodorescu, D. et al. (1990) Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America 87, 9047-9051 (Pubitemid 120007647)
114. Czerniak, B. et al. (1992) Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Human Pathology 23, 1199-1204
115. John, J.G. et al. (2000) Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes, Chromosomes and Cancer 27, 252-263
116. Knowles, M.A. and Williamson, M. (1993) Mutation of H-ras Is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Research 53, 133-139 (Pubitemid 23019388)
117. Fitzgerald, J.M. et al. (1995) Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. Journal of the National Cancer Institute 87, 129-133
118. Zhang, Z.T. et al. (2001) Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 20, 1973-1980
119. Gao, J. et al. (2004) p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Oncogene 23, 687-696 (Pubitemid 38241269)
120. Mo, L. et al. (2007) Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. Journal of Clinical Investigation 117, 314-325 (Pubitemid 46203960)
121. Saison-Behmoaras, T. et al. (1991) Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO Journal 10, 1111-1118 (Pubitemid 21905572)
122. Eastham, J.A. and Ahlering, T.E. (1996) Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line. Journal of Urology 156, 1186-1188 (Pubitemid 26269853)
123. Irie, A. et al. (1999) Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer. Antisense and Nucleic Acid Drug Development 9, 341-349 (Pubitemid 29408068)
124. Choudhary, S. and Wang, H-C.R. (2007) Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells. Molecular Cancer Therapeutics 6, 1099-1111 (Pubitemid 46554581)
125. Choudhary, S. and Wang, H.C. (2007) Proapoptotic activity of oncogenic H-Ras for histone deacetylase inhibitor to induce apoptosis of human cancer HT29 cells. Journal of Cancer Research and Clinical Oncology 133, 725-739 (Pubitemid 47319239)
126. Choudhary, S. and Wang, H.C. (2009) Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction. Journal of Cancer Research and Clinical Oncology 135, 1601-1613
127. Luo, J. et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848
128. Scholl, C. et al. (2009) Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834
129. Zhu, K., Hamilton, A.D. and Sebti, S.M. (2004) Farnesyltransferase inhibitors as anticancer agents: current status. Current Opinion in Investigational Drugs 4, 1428-1435
130. Sebti, S.M. and Hamilton, A.D. (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19, 6584-6593 (Pubitemid 32197696)
131. Sebti, S.M. and Adjei, A.A. (2004) Farnesyltransferase inhibitors. Seminars in Oncology 31, 28-39 (Pubitemid 38241018)
132. Brunner, T.B. et al. (2003) Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Research 63, 5656-5668 (Pubitemid 37187458)
133. Cohen-Jonathan, E. et al. (2000) Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiation Research 154, 125-132 (Pubitemid 30612910)
134. Davies, H. et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (Pubitemid 34716871)
135. Singer, G. et al. (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. Journal of the National Cancer Institute 95, 484-486 (Pubitemid 36432423)
136. Kimura, E.T. et al. (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research 63, 1454-1457 (Pubitemid 36373628)
137. Mansour, S.J. et al. (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265, 966-970 (Pubitemid 24281496)
138. Hoshino, R. et al. (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway inhumantumors. Oncogene 18, 813-822 (Pubitemid 29080340)
139. Katz, M.E. and McCormick, F. (1997) Signal transduction from multiple Ras effectors. Current Opinion in Genetics & Development 7, 75-79 (Pubitemid 27092767)
140. Williams, N.G. and Roberts, T.M. (1994) Signal transduction pathways involving the Raf protooncogene. Cancer and Metastasis Reviews 13, 105-116 (Pubitemid 24053342)
141. Lee, J.T. and McCubrey, J.A. (2003) BAY-43-9006 Bayer/Onyx. Current Opinion in Investigational Drugs 4, 757-763 (Pubitemid 36916718)
142. Hotte, S.J. and Hirte, H.W. (2002) BAY 43-9006: early clinical data in patients with advanced solid malignancies. Current Pharmaceutical Design 8, 2249-2253 (Pubitemid 35189897)
143. DeGrendele, H. (2003) Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors. Clinical Colorectal Cancer 3, 16-18
144. Sebolt-Leopold, J.S. et al. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Medicine 5, 810-816 (Pubitemid 29318616)
145. Allen, L.F., Sebolt-Leopold, J. and Meyer, M.B. (2003) CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Seminars in Oncology 30, 105-116 (Pubitemid 37433401)
146. Rinehart, J. et al. (2004) Multicenter Phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. Journal of Clinical Oncology 22, 4456-4462 (Pubitemid 41185111)
147. Yeh, T.C. et al. (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clinical Cancer Research 13, 1576-1583 (Pubitemid 46450450)
148. Davies, B.R. et al. (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Molecular Cancer Therapeutics 6, 2209-2219 (Pubitemid 47294749)
149. Lojo Rial, C., Wilby, D. and Sooriakumaran, P. (2009) Role and rationale of gene therapy and other novel therapies in the management of NMIBC. Expert Review of Anticancer Therapy 9, 1777-1782
150. Botteman, M.F. et al. (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21, 1315-1330 (Pubitemid 38041357)